Arthneeti

Zydus Lifesciences Q1 FY27 Share Price & Earnings Call Analysis

₹1,184.40+0.76% today
Market cap
₹1.18L Cr
P/E
24.27
ROE
21.25%
PEG
0.76
Price to sales
4.13
Debt to equity
0.46
52W high / low
₹1,215 / ₹861
Sales growth (5Y)
12.45%
EBITDA margin
29.09%
Net profit margin
20.32%
Promoter holding
75.01%
Sales (last year)
₹28,592 Cr

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Guidance scorecard · Q1 FY27 call

What Zydus Lifesci.'s management guided
and where it ranks in Pharmaceuticals & Biotechnology

#54of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • FY27 guidance: Strong double-digit overall revenue growth with mid-teens growth expected in India business.
  • India formulation business: 20% growth in branded portfolio; chronic therapies and innovation portfolios driving sustainable momentum.
  • International markets (EM and Europe): Continued strong growth with new market entries scaling faster than expected.
  • US business: Single-digit growth expected this year, with potential for double-digit growth in FY28 driven by pipeline and branded product scaling.
  • Consumer Wellness: Strong double-digit growth anticipated, continuing 25% like-to-like growth internationally.
  • Medical devices: Growth through investment in focused therapies and differentiation.
  • Medium term: Branded portfolio expected to exceed two-thirds of total revenue, driving improved growth and profitability.

2 more points from Zydus Lifesci.'s call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Zydus Lifesci. said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Capex guidance for the full year is around ₹1,500-₹1,600 crores.
  • Saro (Saroglitazar US launch) will require investments primarily in FY27 and FY28, with build-out phase for first 2 years post-launch in FY28.
  • MedTech and specialty businesses are already invested and baked into current margin guidance.
  • Investments are spread across multiple areas to increase scale and capability, no single large capex item except wellness land acquisition.
Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Zydus Lifesci. said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Aflibercept biosimilar launch in India and its positive initial traction.
  • Business growth drivers including branded business share expanding to over two-thirds.
  • US and international business performance, product launches, and margin guidance.
  • Innovation pipeline, specialty products, acquisition impact, and margin outlook.
Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Zydus Lifesci. rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Zydus Lifesci..

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Zydus Lifesci.

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Zydus Lifesci.

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +5,0115,1404,3694,5055,5346,2085,2375,2696,5286,5746,1236,8647,587
Expenses +3,7553,6343,2233,4033,9034,1243,7763,8824,4024,4854,1075,0485,033
Operating Profit1,2561,5051,1461,1021,6302,0841,4611,3882,1262,0882,0161,8162,554
OPM %25%29%26%24%29%34%28%26%33%32%33%26%34%
Other Income +-566215360160636857-1391557526-263
Interest2818920353225327785101130123
Depreciation179180184195205215234229238238302360508
Profit before tax4841,3281,0069471,5501,9001,2711,1841,6721,9211,6871,3531,660
Tax %28%16%22%23%21%23%29%15%25%23%27%29%19%
Net Profit +3581,1348037901,2461,4829201,0261,2441,5211,2391,0231,341
EPS in Rs2.9310.747.917.8011.7514.119.0610.1711.6414.5812.5110.3612.65

Financials of Zydus Lifesci.

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +8,6519,4279,37611,90513,16614,25315,10215,26517,23719,54723,24227,148
Expenses +6,8967,0957,4749,07410,17411,45511,75811,92313,37814,16316,18318,673
Operating Profit1,7562,3321,9022,8312,9912,7983,3443,3423,8605,3847,0588,475
OPM %20%25%20%24%23%20%22%22%22%28%30%31%
Other Income +45112127111183-264-1712,581-42229350-7
Interest6853459119434216412713081166439
Depreciation2872923735395996967257137237649161,408
Profit before tax1,4462,0991,6122,3122,3821,4952,2855,0842,5854,8326,0276,621
Tax %18%8%8%24%22%21%6%10%23%20%23%24%
Net Profit +1,1881,9641,5171,8101,8991,2042,1854,6182,0923,9734,6735,124
EPS in Rs11.2418.8914.5317.3518.0611.4920.8443.8319.3738.3644.9750.09
Dividend Payout %21%17%22%20%19%30%17%6%31%8%24%2%

Financials of Zydus Lifesci.

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital102102102102102102102102101101101101
Reserves4,1495,5976,8588,64210,28410,27312,89016,89717,41519,72923,85227,011
Borrowings +2,6512,4425,2075,4077,8997,9864,5844,2211,1958043,21312,496
Other Liabilities +2,1442,2082,9373,6324,9455,1156,1896,4216,8518,2019,52312,799
Total Liabilities9,04710,35015,10417,78323,23123,47723,76527,64225,56228,83436,68952,407
Fixed Assets +3,3523,7485,7556,48312,16412,23012,13312,25311,52112,36813,13426,639
CWIP7989511,5431,5278377427836611,2012,4232,6921,166
Investments1544164357466747658303,2881,5471,2206,4087,540
Other Assets +4,7435,2357,3719,0289,5569,74010,01911,43911,29412,82214,45617,062
Total Assets9,04710,35015,10417,78323,23123,47723,76527,64225,56228,83436,68952,407

Financials of Zydus Lifesci.

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +9941,8941,3129191,2822,5053,2932,1042,6893,2286,7772,117
Cash from Investing Activity +-465-860-2,872-974-3,977-1,012-8351,1371,178-1,492-8,377-8,296
Cash from Financing Activity +-351-9352,316521,885-1,094-2,549-868-4,400-1,8102,0145,807
Net Cash Flow17899756-3-811399-902,373-534-75414-373
Free Cash Flow498936-1,623-1162361,6172,4461,0501,6972,3455,116-530
CFO/OP79%109%81%54%65%100%109%83%85%84%122%44%

Financials of Zydus Lifesci.

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6768899811094768094976373
Inventory Days175158193211208207227245197202227282
Days Payable125154165167149151155141123125133142
Cash Conversion Cycle11871116142169150148184168175158212
Working Capital Days6-1-341710-19-6197088337
ROCE %23%28%16%18%15%11%14%13%15%22%24%21%

Guidance history

How Zydus Lifesci.'s guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlanned——
Q4 FY26 call →20–40%Down 0–2%Planned——
Q3 FY26 call →20–40%FlatPlannedNone planned—
Q2 FY26 call →10–20%FlatPlannedPlanned—

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

77out of 100

Momentum score · price trend

77 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+18.1%73%
Last 6 months+32.8%82%
Last 3 months+6.2%74%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Zydus Lifesci.: 0.4 × 73 + 0.4 × 82 + 0.2 × 74 = 77.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Zydus Lifesci.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd